A Multicenter Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Investigate Efficacy, Safety and Pharmacokinetics after Dose Escalation in Japanese Subjects with Crohn's Disease

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-004121-13

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To investigate efficacy, safety and pharmacokinetics after dose escalation for the subjects who lost response to adalimumab in Japanese patients with Crohn's disease.


Critère d'inclusion

  • Crohn’s Disease

Liens